Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — AusBiotech Invest (October 2018)
16 slides from Kazia Therapeutics's conference presentation, Oct 30, 2018
Slide 1: Cancer-focused biotech with two clinical-stage programs
Cancer-focused biotech with two clinical-stage programs Presentation to AusBiotech Invest #AusBioInv Dr James Garner Chief Executive Officer & Executive Director Melbourne, VIC 30 October 2018
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 3: Investment Highlights
Investment Highlights 1 Cancer drug developer with two distinct therapies in human trials - GDC-0084 in phase II clinical trial for brain cancer - Two clinical collaborations with GDC-0084 in other forms of brain cancer - Cantrixil in phase I clinical trial for ovarian cancer 2 Lead program, GDC-008
Slide 4: Four clinical trials in progress across two programs
Kazia has four clinical trials in progress across two programs, at leading centres in US and Australia Preclinical Phase I Phase II Phase III GDC-0084 PI3K / mTOR Inhibitor Licensed from Genentech in October 2016 Glioblastoma Multiforme (GBM) (Kazia-sponsored) Ovarian Cancer (Kazia-sponsored) TRX-E-
Slide 5: Clinical trials news flow provides at least four value-driving inflection points during 2018-19
Clinical trials news flow provides at least four value-driving inflection points during 2018-19 GDC-0084 Glioblastoma Multiforme (GBM) Cantrixil Ovarian Cancer Preliminary data from phase 1 study in ovarian cancer Completion of Part A of phase 1 study (safety and dosing)* *Full publication plans to
Slide 6: Glioblastoma is the most common and most aggressive form of primary brain cancer
Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung 14 million cancer cases per annum Breast Colon Prostate Stomach No clear cause or strong risk factors 3-4 months untreated survival 12-15 months average survival with treatment Any age, but most common in 60s
Slide 7: Growing public attention for brain cancer highlights need for new treatment options
Growing public attention for brain cancer highlights need for new treatment options There is increasing recognition of the need to find treatment options for patients with brain cancer Senator John McCain’s diagnosis in July 2017 highlighted glioblastoma and focused attention on the need for new tre
Slide 8: Current standard of care is essentially ineffective in approximately 65% of GBM cases
Current standard of care is essentially ineffective in approximately 65% of GBM cases Source: ME Hegi, A-C Diserens, T Gorlia, et al. (2005). N Engl J Med 352:997-1003 Standard of Care (‘Stupp Regimen’) Debulking surgery where possible Radiotherapy + temozolomide Temozolomide maintenance therapy 6 w
Slide 9: The PI3K class is well-proven, but GDC-0084 is unique and differentiated
The PI3K class is well-proven, with three approved therapies, but GDC-0084 is unique and differentiated FDA Approved July 2014 (blood cancers) [accelerated approval] FDA Approved September 2017 (blood cancers) [accelerated approval] FDA Approved October 2018 (blood cancers) [accelerated approval] In
Slide 10: In GDC-0084 phase I, patients showed a metabolic partial response
In GDC-0084 phase I, 7 / 27 patients (26%) showed a ‘metabolic partial response’ to treatment Analysis courtesy of Professor Ben Ellingson, UCLA Brain Tumor Imaging Laboratory Pre-Dosing On GDC-0084 Pre-Dosing On GDC-0084
Slide 11: Multipart phase II design allows for frequent data read-outs
Multipart phase II design allows for frequent data read-outs to inform partnering and early approval Note: timelines are estimated, and subject to periodic revision based on recruitment performance and treatment effect Step 1 Dose Optimisation Step 2 Expansion Cohort Step 3 Planned Registration Tria
Slide 12: Brain cancer represents a substantial commercial opportunity for GDC-0084
Brain cancer represents a substantial commercial opportunity for GDC-0084 Glioblastoma HER2+ Breast Cancer Approximately 130,000 patients per annum worldwide Approximately 340,000 patients per annum worldwide $2.3 billion estimated market opportunity in 2024 [Transparency Research] $12.7 billion est
Slide 13: Other companies focused on the PI3K pathway have been highly-valued
Single asset company with one PI3K inhibitor in phase I human trials US$ 140 million Market Cap One PI3K inhibitor in phase II human trials, one other drug in phase III, and two in animal testing US$ 430 million Market Cap One PI3K inhibitor in phase II human trials Acquired by big pharma in 2011 fo
Slide 14: Kazia is now well-funded to see both programs through key data read-outs
Kazia is now well-funded to see both programs through key data read-outs in calendar 2019 *NOX shares valued as at October 2018 $9.3M Current assets as at 30 June 2018 ~$3.5M* Shares in Noxopharm (ASX:NOX) $3.4M Proceeds (pre-costs) from institutional placement in Oct 18 Current funding allows:- Com
Slide 15: Investment Highlights
Investment Highlights 1 Cancer drug developer with two distinct therapies in human trials - GDC-0084 in phase II clinical trial for brain cancer - Two clinical collaborations with GDC-0084 in other forms of brain cancer - Cantrixil in phase I clinical trial for ovarian cancer 2 Lead program, GDC-008
Slide 16: Kazia Therapeutics contact
SKAZIA e THERAPEUTICS www.kaziatherapeutics.com info@kaziatherapeutics.com
Kazia Therapeutics — AusBiotech Invest (October 2018) on 6ix